Biosimilars are a
In the U.S., Biosimilars could lead to over $130 billion is savings by 2025, and have been used in over 364 million days of patient therapy.
Access! 2023: Feb. 13-15 & IGBA Annual Conference: Feb. 15-16
Don’t wait! This year, AAM is hosting two premier conferences back to back in Orlando, Florida. Access!, AAM’s annual meeting and the 25th IGBA Annual Conference, will bring together key experts, policymakers, and scientists to chart a path forward for the generic and biosimilars industries. Don’t wait! Sign up today!
Festival of Biologics: March 20-23
This year, AAM and its Biosimilars Council are official partners of the Festival of Biologics! This event, held in San Diego, California, gives you the opportunity to share research, create new partnerships, and tackle the clinical trials, manufacturing and commercial challenges involved in bringing new therapies to market. Register now!
Advocacy
The Biosimilars Council advocates to increase patient access to lifesaving, affordable biosimilar medicines.
Our members include manufacturers and stakeholders working to develop biosimilar medicines for the U.S. market
Biosimilars approved in the U.S.
$130
Billion in potential savings for patients and payers
364
Million days of patient therapy where biosimilars were used
Million additional days of patient therapy
The Benefits of Biosimilars
Expanding access to biosimilars has proven successful in driving down the cost of life-saving therapies.
This increases access to needed medications for patients, strengthens our economy and benefits our society.
View resources for:
Recent Blogs & Resources
What Patients Are Saying
Expanding access to biosimilars has proven successful in driving down the cost of life-saving therapies.
“Because I have an incurable form of non-Hodgkin lymphoma, I know my medication journey will continue. It is nice to know that when I need a biosimilar again, it will be there for me.”
Helen, 41, Florida
Listen to their stories.
You Can Make A Difference
As the role of biosimilar medicines in our health care system continues to grow, it is essential that patients advocate for affordable biosimilars with their lawmakers. Subscribe to the Biosimilars Bulletin and for alerts on policies that affect your access to these life-saving medicines.
